Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Account Payables (2016 - 2025)

Heron Therapeutics' Change in Account Payables history spans 14 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 298.75% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached -$2.7 million, down 132.06%, while the annual FY2025 figure was -$2.7 million, 132.06% down from the prior year.
  • Change in Account Payables reached -$3.0 million in Q4 2025 per HRTX's latest filing, down from -$20000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $9.6 million in Q2 2021 to a low of -$7.3 million in Q3 2022.
  • Average Change in Account Payables over 5 years is $423450.0, with a median of -$29000.0 recorded in 2024.
  • The largest YoY upside for Change in Account Payables was 545.4% in 2024 against a maximum downside of 386.07% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at -$2.1 million in 2021, then plummeted by 59.56% to -$3.3 million in 2022, then skyrocketed by 141.54% to $1.4 million in 2023, then increased by 10.22% to $1.5 million in 2024, then tumbled by 298.75% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Change in Account Payables are -$3.0 million (Q4 2025), -$20000.0 (Q3 2025), and -$296000.0 (Q2 2025).